刘晓东简介


刘晓东，男，1960年1月出生，博士；中国药科大学药学院副院长，教授，博士生导师。主要研究方向：研究方向：中药药物代谢动力学、疾病状态下药物代谢动力学、血脑屏障与药物转运、药物相互作用和创新药物的药代动力学研究以及生理药物代谢动力学模型。近年来致力于基于机制的药物代谢动力学模型与转化医学关系研究。

1、主要社会兼职情况
现为中国药理学会药物代谢动力学专业委员会副主任委员、中国药理学会数学药理学会理事、中国药学会应用药理专业委员会委员、国家药品监督管理局药品审评专家和江苏省药品审评专家、江苏省青蓝工程跨世纪省级学术带头人培养对象和江苏省“333”工程培养对象（第二层次）。2009年度入选江苏高等学校优秀科技创新团队带头人，享受国务院政府特殊津贴。为《中国药科大学学报》、《中国药师》、《中国临床药理学与治疗学》、《World?Journal of Pharmacology》编委、《Planta Med》、《Acta Pharmacologica sinica》、《Biochemical Pharmacology》等学术期刊的审稿专家。

2、近5年来主持科研项目情况
1. 国家自然科学基金面上项目，81373482、?肝损伤与血脑屏障上P-GP和MRP2等ABC类转运体功能/表达改变及其对脑内药物处置的影响、2014/01-2017/12、65万元、在研、主持。
2. 国家自然科学基金小额探索项目，81273587、糖尿病状态下肝CYP3A等CYP450酶诱导对药物代谢影响及其在糖尿病病情发展中的作用、2013/01-2013/12、16万元、已结题、主持。
3. 国家自然科学基金面上项目，81072693、糖尿病状态下P-糖蛋白等ABC转运体功能与表达的组织特异性改变及其对药物体内处置影响、2011/01-2013/12、33万元、已结题、主持。
4. 国家自然科学基金面上项目，30873123、基于肠道黏膜系统诠释口服难吸收中药复方的全身作用、2009/01-2011/12、28万元、已结题、主持。

3、 近5年来发表有代表性学术论文（*通讯作者）
1. Liu L, Liu XD*. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol. 2014 Dec 10; 5:273.
2. Zhang J, Zhang M, Sun B, Li Y, Xu P, Liu C, Liu L*, Liu X*. Hyperammonemia enhances the function and expression of P-glycoprotein and Mrp2 at the blood-brain barrier through NF-κB. J Neurochem. 2014 Dec; 131(6):791-802.
3. Xu D, Li F, Zhang M, Zhang J, Liu C, Hu MY, Zhong ZY, Jia LL, Wang DW, Wu J, Liu L*, Liu XD*. Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. Acta Pharmacol Sin. 2014 Sep; 35(9): 1215-25. doi: 10.1038/aps.2014.39.
4. Liu C, Hu MY, Zhang M, Li F, Li J, Zhang J, Li Y, Guo HF, Xu P, Liu L*, Liu XD*. Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats. Metabolism. 2014 Oct; 63(10): 1342-51. doi: 10.1016/j.metabol.2014.06.015.?
5. Li J, Guo HF, Liu C, Zhong Z, Liu L*, Liu XD*. Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. Clin Pharmacokinet. 2015 Feb; 54(2):179-93. doi: 10.1007/s40262-014-0192-8.
6. Li F, Zhang M, Xu D, Liu C, Zhong ZY, Jia LL, Hu MY, Yang Y, Liu L*, Liu XD*. Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacol Sin. 2014; 35(6): 792-805.
7. Li J, Wang X, Liu H, Guo H, Zhang M, Mei D, Liu C, He L, Liu L*, Liu X*. Impaired hepatic and intestinal ATP-binding cassette transporter G5/8 was associated with high exposure of β-sitosterol and the potential risks to blood-brain barrier integrity in diabetic rats. J Pharm Pharmacol. 2014; 66(3):428-36.
8. Hu N, Hu MY, Duan R, Liu C, Guo HF, Zhang M, Yu YL, Wang XT, Liu L*, Liu XD*. The increased levels of fatty acids contributed to induction of hepatic CYP3A4 activityinduced by diabetes. An in vitro evidence from HepG2 cell and Fa2N-4 cell lines. J Pharmacol Sci. 2014; 124(4):433-44.
9. Jia LL, Zhong ZY, Li F, Ling ZL, Chen Y, Zhao WM, Li Y, Jiang SW, Xu P, Yang Y, Hu MY, Liu L*, Liu XD*. The aggravation of clozapine-induced hepatotoxicity by glycyrrhetinic Acid in rats. J Pharmacol Sci. 2014;124(4):468-79.
10. Guo H, Liu C, Li J, Zhang M, Hu M, Xu P, Liu L*, Liu X*. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. J Pharm Sci. 2013; 102(8): 2819-36.
11. Liu C, Zhang M, Hu MY, Guo HF, Li J, Yu YL, Jin S, Wang XT, Liu L*, Liu XD*. Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. J Endocrinol. 2013; 217(2):185-96. [IF: 4.058]
12. Yu Y, Wang X, Liu C, Yao D, Hu M, Li J, Hu N, Liu L*, Liu X*. Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicol Appl Pharmacol. 2013; 266(3): 375-84.
13. Li F, Wang D, Xu P, Wu J, Liu L, Liu X*. Identification of the metabolites of anti-inflammatory compound clematichinenoside AR in rat intestinal microflora. Biomed Chromatogr. 2013 Jul 12. doi: 10.1002/bmc.2991.
14. Yang Y, Chen Y, Zhong ZY, Zhang J, Li F, Jia LL, Liu L, Zhu X*, Liu XD*. Validated LC-MS/MS assay for quantitative determination of deoxypodophyllotoxin in rat plasma and its application in pharmacokinetic study. J Pharm Biomed Anal. 2014;88:410-5.
15. Wang J, Xia S, Xue W, Wang D, Sai Y, Liu L, Liu X*. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013; 50(3-4):290-302.
16. Jin S, Wang XT, Liu L, Yao D, Liu C, Zhang M, Guo HF, Liu XD*. P-glycoprotein and multidrug resistance-associated protein 2 are oppositely altered in brain of rats with thioacetamide-induced acute liver failure. Liver Int. 2013; 33(2): 274-82.
17. Wang D, Li F, Li P, Zhang J, Liu L, Xu P, Zhou L, Liu X*. Validated LC-MS/MS assay for the quantitative determination of clematichinenoside AR in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2012; 26(10):1282-5.
18. Liu HY, Liu L, Li J, Duan R, Hu N, Guo HF, Zhong ZY, Liu XD*. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus. Drug Metab Dispos. 2012; 40(6): 1104-1112.
19. Duan R, Hu N, Liu HY, Li J, Guo HF, Liu C, Liu L*, Liu XD*. Biphasic regulation of P-glycoprotein function and expression by NO donors in Caco-2 cells. Acta Pharmacol Sin. 2012: 33(6): 767-74.
20. Wang XT, Li J, Liu L, Hu N, Jin S, Liu C, Mei D, Liu XD*. Tissue cholesterol content alterations in streptozotocin-induced diabetic rats. Acta Pharmacol Sin. 2012; 33(7): 909-17.
21. Mei D, Li J, Liu HY, Liu L, Wang XT, Guo HF, Liu C, Duan R, Liu XD*. Induction of multidrug resistance-associated protein 2 in liver, intestine and kidney of streptozotocin-induced diabetic rats. Xenobiotica. 2012; 42(8): 709-18
22. Wang P, Pan X, Chen GM, Li J, Liu L, Liu XD*, Jin S, Xie L, Wang GJ. Increased Exposure of Vitamin A by Chrysanthemum morifolium Ramat Extract in Rat Was Not via Induction of CYP1A1, CYP1A2, and CYP2B1. J Food Sci. 2012; 77(6): H121-27.
23. Yao D, Liu L, Jin S, Li J Liu XD*. Overexpression of multidrug resistance-associated protein 2 in the brain of pentylenetetrazole-kindled rats. Neuroscience. 2012; 227: 283-92.
24. Liu L, Yu YL, Liu C, Wang XT, Liu XD*, Xie L. Insulin deficiency induces abnormal increase in intestinal disaccharidase activities and expression under diabetic states, evidences from in vivo and in vitro study. Biochem Pharmacol. 2011; 82(12): 1963-70.
25. Liu L, Pan X, Liu HY, Liu XD*, Yang HW, Xie L, Cheng JL, Fan HW, Xiao DW. Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans. Acta Pharmacol Sin. 2011; 32(10): 1285-93.
26. Zhang LL, Lu L, Jin S, Jing XY, Yao D, Hu N, Liu L, Duan R, Liu XD*, Wang GJ, Xie L. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats. Acta Pharmacol Sin. 2011; 32(7): 956-66.
27. Liu X, Jing XY, Jin S, Li Y, Liu L, Yu YL, Liu XD*, Xie L. Insulin suppresses the expression and function of breast cancer resistance protein in primary cultures of rat brain microvessel endothelial cells. Pharmacol Rep. 2011; 63(2): 487-93.
28. Pan X, Wang P, Hu N, Liu L, Liu XD*, Xie L, Wang GJ. A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans. Drug Metab Pharmacokinet. 2011; 26(4): 387-98.
29. Chen GM, Hu N, Liu L, Xie SS, Wang P, Li J, Xie L, Wang GJ, Liu XD*. Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. Xenobiotica. 2011; 41(6): 494-500.
30. Yao D, Yang ZH, Liu L, Li J, Yu YL, Zhang LL, Pan X, Liu XD*, Xie L, Wang GJ. Verapamil exerts biphasic modulation on phenobarbital transport across the blood-brain barrier: evidence from an in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 2011; 383(4): 393-402.
31. Hu N, Xie S, Liu L, Wang X, Pan X, Chen G, Zhang L, Liu H, Liu X*, Liu X, Xie L, Wang G. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos. 2011; 39(3): 419-25.
32. Liu Y, Liu L, Lu S, Wang D, Liu X*, Xie L, Wang G.Impaired amyloid β-degrading enzymes in brain of streptozotocin-induced diabetic rats. J Endocrinol Invest. 2011; 34(1): 26-31.
33. Jing X, Liu X, Wen T, Xie S, Yao D, Liu X*, Wang G, Xie L.Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats. Br J Pharmacol. 2010; 159(7): 1511-22.
34. Liu L, Yu YL, Yang JS, Li Y, Liu YW, Liang Y, Liu XD*, Xie L, Wang GJ. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 2010; 381(4): 371-81.
35. Xie SS, Hu N, Jing XY, Liu XD*, Xie L, Wang GJ, Liu CH. Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. J Pharm Pharmacol. 2010; 62(4): 440-7.
36. Yu S, Yu Y, Liu L, Wang X, Lu S, Liang Y, Liu X*, Xie L, Wang G. Increased plasma exposures of five protoberberine alkaloids from Coptidis Rhizoma in streptozotocin-induced diabetic rats: is P-GP involved? Planta Med. 2010; 76(9): 876-81.
37. Yu Y, Liu L, Wang X, Liu X, Liu X*, Xie L, Wang G. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol. 2010; 79(7): 1000-6.
38. Liu L, Deng YX, Liang Y, Pang XY, Liu XD*, Liu YW, Yang JS, Xie L, Wang GJ. Increased oral AUC of baicalin in streptozotocin-induced diabetic rats due to the increased activity of intestinal beta-glucuronidase. Planta Med. 2010; 76(1): 70-5.

4、近年来获厅级以上奖励情况
1) 2013年/江苏省优秀硕士学位论文/急性和慢性肝损伤对大鼠脑内P-GP和MRP2功能及表达的影响/导师
2) 2009年/江苏省优秀博士学位论文/糖尿病导致血脑屏障上P-糖蛋白 下调的机制和治疗学意义研究/导师
3) 2008年/江苏省优秀硕士学位论文/黄连解毒汤对尼莫地平在大鼠血脑屏障上转运的影响/导师
4) 2007年/国家科技进步二等奖/临床前药物代谢动力学关键技术与研究体系/排名第2
5) 2004年/江苏省科学技术进步一等奖/创新药物吸收、代谢、分布与排泄新理论与新模型研究/排名第2

5、指导研究生情况
1999年开始指导药代动力学专业硕士研究生；已毕业获学位硕士生共40余人；多名毕业生分别进入北京大学医学部、上海药物研究所等知名高校攻读博士学位和GSK、诺华、恒瑞等著名企业。现正在指导博士研究生6人，硕士生11人。